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Introduction 
Erythroderma is defined as erythema and 
desquamation of greater than 90% of the body 
surface area and is often the clinical sign of a wide 
range of cutaneous and systemic diseases [1]. 
Although psoriasis is the most common underlying 
cause, other conditions in the differential diagnosis 
include drug-related reactions, atopic dermatitis, 
contact dermatitis, pityriasis rubra pilaris, and 
lymphoproliferative disorders. Erythroderma is 
associated with an increased risk of fluid and 
electrolyte abnormalities, high output cardiac 
failure, secondary bacterial infections, and potential 
malignancy, making a thorough evaluation for the 
underlying diagnosis critical [2]. Herein, we present 
an erythrodermic patient with cutaneous findings 
consistent with a spongiotic process on 
histopathology. However, the patient was found to 
have circulating atypical T-lymphocytes, raising the 
possibility of primary Sézary syndrome. 
 
Case Synopsis 
An 81-year-old man presented to the Skin and 
Cancer Unit at the Ronald O. Perelman Department 
of Dermatology for the evaluation of a generalized, 
pruritic, and scaly eruption. He also reported diffuse 
hair loss for several months. He denied any new or 
recent environmental exposures, personal or family 
history of atopy, or oral medications. Physical 
examination was confluent blanching, erythematous 
patches associated with superficial desquamation on 
the head, neck, trunk, and upper and lower 
extremities, covering >95% of his total body surface 
(Figure 1). There were no islands of sparing, palpable 
lymphadenopathy, vesicles, or bullae. 
A complete blood count was normal except for an 
elevated eosinophil level of 14% (reference range: 
0.8-7.0%) and an elevated absolute eosinophil count 
of 1.3×103/μL (reference range: 0.0-0.5×103/μL). A 
comprehensive metabolic panel was normal except 
for an elevated creatinine level of 1.44mg/dL 
(reference range: 0.7-1.3mg/dL). A lactate 
dehydrogenase level was within normal limits. A 
serum flow cytometry showed that 43% of the 
circulating lymphocytes were immunopheno-
typically aberrant T-cells. A T-cell receptor (TCR) 
gamma chain gene rearrangement study on 
peripheral blood was positive for a monoclonal T-cell 
population. No HTLV-1 DNA was detected. 
Two broad shaves were performed of the left flank 
and right medial upper arm. There was a superficial 
Abstract 
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perivascular and patchy band-like lymphohistiocytic 
infiltrate with numerous eosinophils. Lymphocytes 
and eosinophils extended into the epidermis, which 
was hyperplastic with prominent spongiosis (Figure 
2). A specimen submitted for direct 
immunofluorescence failed to reveal reactivity for 
C3, IgA, IgG, IgM, or fibrinogen. TCR gene 
rearrangement studies on the left flank skin biopsy 
specimen was negative. 
A computed tomography (CT) of the 
abdomen/pelvis without intravenous (IV) contrast 
showed no hepatosplenomegaly or 
lymphadenopathy. A CT of the chest without IV 
contrast showed no evidence of intrathoracic 
lymphoma, cutaneous nodules, or plaques. 
 
Case Discussion 
Sezary syndrome (SS) is a rare and more aggressive 
variant of cutaneous T-cell lymphoma (CTCL) that 
occurs at an incidence rate of 0.1-0.3 per 1,000,000 
person-years in the United States and represents 
2.5% of all CTCL [3, 4]. The disease occurs most 
commonly in older adults, males, and, in contrast to 
other types of CTCL, Caucasians [4]. The World Health 
Organization (WHO) and European Organization for 
Research and Treatment of Cancer (EORTC) define SS 
in broad terms, which includes desquamative 
erythroderma, lymphadenopathy, and leukemic 
involvement [5]. Generalized lymphadenopathy, 
Figure 1. A) Face, chest, upper and lower extremities with 
confluent blanching, erythematous patches associated with 
superficial desquamation. B) Back with confluent blanching, 
erythematous patches associated with superficial 
desquamation. 
Figure 2 Shave biopsy with hematoxylin and eosin stains (40×) 
showing a superficial perivascular and patchy band-like 
lymphohistiocytic infiltrate with numerous eosinophils. 
Lymphocytes and eosinophils extended into the epidermis, which 
was hyperplastic with prominent spongiosis.
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palmoplantar keratoderma, nail abnormalities, and 
alopecia are other commonly associated findings [6]. 
Although cutaneous infiltration of atypical T 
lymphocytes is helpful in the diagnosis of SS, a 
significant number of skin biopsies show non-
specific findings [7, 8]. In our patient, no atypical 
lymphocytes were seen on histological examination 
and TCR gene rearrangement studies performed on 
the biopsy specimen were negative. Therefore, if 
malignancy remains in the differential diagnosis for 
the work-up of erythroderma, evaluation of the 
peripheral blood is recommended. Abnormalities in 
SS include >1000 Sézary cells, which is defined as 
circulating malignant T lymphocytes with 
cerebriform nuclei, an increased CD4/CD8 ratio of 
>10 by flow cytometry, a loss of CD7 expression in 
more than 40% or loss of CD26 expression in more 
than 30% of circulating T cells, and evidence of a 
circulating T-cell clone by T-cell receptor gene 
rearrangement [5]. 
Recent studies demonstrate a median survival of 4.0 
years and overall survival of 42.3% at 5 years after 
diagnosis of SS [6]. Because SS is so rare, its prognosis 
is often grouped with CTCL staging and is equivalent 
to stage IV disease. The disease is further stratified by 
presence or lack of visceral involvement. Older age 
(>60 years) and increased lactate dehydrogenase at 
diagnosis and may predict a worse prognosis [5]. 
The low incidence of SS has limited the study of 
effective therapies and treatment options and there 
is little consensus on initial treatment choice. First-
line therapies for SS may include extracorporeal 
photophoresis, subcutaneous interferon-α, oral 
bexarotene, and low-dose oral, subcutaneous, or 
intramuscular methotrexate (≤100mg per week), [7]. 
Systemic therapy may also be combined with various 
skin-directed therapies such as psoralen plus 
ultraviolet A (PUVA), topical nitrogen mustard, and 
total skin electron beam therapy (TSEBT), [7]. 
Localized radiation therapy may be added for local 
control of skin tumors or lymph node involvement; 
patients with visceral involvement are often treated  
with histone deacetylase inhibitors (e.g., vorinostat 
or romidepsin), [9]. 
Cutaneous colonization with Staphylococcus aureus 
may influence the disease activity of SS, and the 
eradication of S. aureus with antibiotics in patients 
with erythrodermic mycosis fungoides (MF) and SS 
has been shown to lead to a significant improvement 
of erythroderma and skin disease burden [10]. For 
symptomatic management of pruritus, which is 
often the most debilitating symptom and should be 
addressed to improve overall quality of life, topical 
corticosteroids and emollients along with systemic 
medications such as antihistamines, doxepin, and 
gabapentin should be considered. 
Recently, mogamulizumab, a humanized 
monoclonal antibody directed against the 
chemokine receptor CCR4, was approved for 
treatment of adults with SS after failure of at least 
one prior systemic therapy [11]. A randomized, 
controlled phase III trial comparing mogamulizumab 
to vorinostat showed that treatment with 
mogamulizumab resulted in a significant 
improvement in progression-free survival (7.7 versus 
3.1 months), overall response (37 versus 2 percent), 
and quality of life for patients with SS who failed a 
previous systemic therapy [12]. 
 
Conclusion 
Our patient was initially started on mycophenolate 
mofetil with short-term cyclosporine as a bridge 
prior to the diagnosis of SS. However, cyclosporine 
was discontinued owing to elevating creatinine. He 
was also treated with class I topical corticosteroids 
and antihistamines, which resulted in partial 
symptomatic improvement. He was eventually 
started on methotrexate by the 
hematology/oncology department and 
phototherapy with improvement in his 
erythroderma and his pruritus. 
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